Sign In
Buy ELAN
$23.18
-0.710 (-2.97%)
At Close: Jun 23, 2026
The Schall Law Firm Urges Investor Participation In A Securities Fraud Inquiry Into Elanco Animal Health Incorporated
11:00am, Saturday, 21'st Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
Elanco's President & CEO on Zenrelia Approved by FDA
06:00pm, Friday, 20'th Sep 2024
Jeff Sessions, Elanco Animal Health President & CEO speak with Alix Steel and Vonnie Quinn about new pet drug Zenrelia being approved by the FDA. -------- More on Bloomberg Television and Markets Like
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
10:35am, Friday, 20'th Sep 2024
On Thursday, the FDA approved Elanco Animal Health Incorporated's ELAN Zenrelia, a once-daily oral JAK inhibitor for the control of pruritus (itching) associated with allergic dermatitis and atopic de
Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology
03:08pm, Thursday, 19'th Sep 2024
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis Elanco enters the estimated $1.7 billion global canine dermatology mar
Calls of the Day: Elanco Animal Health CEO, Casey's General Store, GE Vernova, Spotify
01:28pm, Thursday, 19'th Sep 2024
The Investment Committee discuss the latest Calls of the Day.
FDA approves Elanco's dermatitis treatment for dogs
12:50pm, Thursday, 19'th Sep 2024
The U.S. Food and Drug Administration has approved Elanco Animal Health's dermatitis treatment for dogs, the health regulator's website showed on Thursday.
Elanco Animal Health Incorporated May Have Defrauded The Public And The Schall Law Firm Seeks Investor Participation In An Inquiry
11:00am, Thursday, 19'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
Investors In Elanco Animal Health Incorporated Are Urged To Join The Schall Law Firm In A Securities Fraud Investigation
11:00am, Tuesday, 17'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Anima
Elanco Provides Update on Contract Manufacturing Partner
07:30am, Friday, 13'th Sep 2024
GREENFIELD, Ind. , Sept. 13, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (Tri
